Evaluation of enzyme immunoassays for antibody to human T-lymphotropic viruses type I/II

R. L. Kline, Thomas C Quinn, T. Brothers, Neal A Halsey, R. Boulos, M. D. Lairmore

Research output: Contribution to journalArticle

Abstract

To evaluate the sensitivity and specificity of HTLV-I/ II assays, serum from 1100 pregnant Haitian women was tested with seven commercially available HTLV I/II assays. Serum that was found to be reactive in any assay was analysed by western blot and all indeterminate samples were further characterised by radioimmunoprecipitation assays (RIPA). 59 (5·4%) samples were HTLV I/II antibody positive by western blot and/or RIPA. The sensitivity of these seven assays ranged from 93·2% to 100%, with the 'Recombinant HTLV-I' (Cambridge Bioscience) and 'Serodia HTLV-I' (Fujirebio) assays having the highest sensitivity (100%). The specificity of these assays ranged from 98·4% to 100%, with the Abbott assay having the highest specificity (99·5%, 100%) according to two different methods of evaluation. Whether the antigens used in any assay were whole disrupted virus or recombinant gene products made no difference. The low positive predictive values of some of these assays (71·8-91·7%), even in a high prevalence population, and the need for RIPA to test indeterminate sera, indicate that for routine screening of blood donors there is still room for improvement both in screening and confirmatory assays for HTLV-I/II.

Original languageEnglish (US)
Pages (from-to)30-33
Number of pages4
JournalThe Lancet
Volume337
Issue number8732
DOIs
StatePublished - Jan 5 1991

Fingerprint

Human T-lymphotropic virus 2
Human T-lymphotropic virus 1
Immunoenzyme Techniques
Radioimmunoprecipitation Assay
Antibodies
HTLV-II Antibodies
HTLV-I Antibodies
Western Blotting
Serum
Blood Donors
Pregnant Women
Viruses
Antigens
Sensitivity and Specificity
Population
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Evaluation of enzyme immunoassays for antibody to human T-lymphotropic viruses type I/II. / Kline, R. L.; Quinn, Thomas C; Brothers, T.; Halsey, Neal A; Boulos, R.; Lairmore, M. D.

In: The Lancet, Vol. 337, No. 8732, 05.01.1991, p. 30-33.

Research output: Contribution to journalArticle

Kline, R. L. ; Quinn, Thomas C ; Brothers, T. ; Halsey, Neal A ; Boulos, R. ; Lairmore, M. D. / Evaluation of enzyme immunoassays for antibody to human T-lymphotropic viruses type I/II. In: The Lancet. 1991 ; Vol. 337, No. 8732. pp. 30-33.
@article{1de128f181734d779848781da09a8f16,
title = "Evaluation of enzyme immunoassays for antibody to human T-lymphotropic viruses type I/II",
abstract = "To evaluate the sensitivity and specificity of HTLV-I/ II assays, serum from 1100 pregnant Haitian women was tested with seven commercially available HTLV I/II assays. Serum that was found to be reactive in any assay was analysed by western blot and all indeterminate samples were further characterised by radioimmunoprecipitation assays (RIPA). 59 (5·4{\%}) samples were HTLV I/II antibody positive by western blot and/or RIPA. The sensitivity of these seven assays ranged from 93·2{\%} to 100{\%}, with the 'Recombinant HTLV-I' (Cambridge Bioscience) and 'Serodia HTLV-I' (Fujirebio) assays having the highest sensitivity (100{\%}). The specificity of these assays ranged from 98·4{\%} to 100{\%}, with the Abbott assay having the highest specificity (99·5{\%}, 100{\%}) according to two different methods of evaluation. Whether the antigens used in any assay were whole disrupted virus or recombinant gene products made no difference. The low positive predictive values of some of these assays (71·8-91·7{\%}), even in a high prevalence population, and the need for RIPA to test indeterminate sera, indicate that for routine screening of blood donors there is still room for improvement both in screening and confirmatory assays for HTLV-I/II.",
author = "Kline, {R. L.} and Quinn, {Thomas C} and T. Brothers and Halsey, {Neal A} and R. Boulos and Lairmore, {M. D.}",
year = "1991",
month = "1",
day = "5",
doi = "10.1016/0140-6736(91)93343-8",
language = "English (US)",
volume = "337",
pages = "30--33",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "8732",

}

TY - JOUR

T1 - Evaluation of enzyme immunoassays for antibody to human T-lymphotropic viruses type I/II

AU - Kline, R. L.

AU - Quinn, Thomas C

AU - Brothers, T.

AU - Halsey, Neal A

AU - Boulos, R.

AU - Lairmore, M. D.

PY - 1991/1/5

Y1 - 1991/1/5

N2 - To evaluate the sensitivity and specificity of HTLV-I/ II assays, serum from 1100 pregnant Haitian women was tested with seven commercially available HTLV I/II assays. Serum that was found to be reactive in any assay was analysed by western blot and all indeterminate samples were further characterised by radioimmunoprecipitation assays (RIPA). 59 (5·4%) samples were HTLV I/II antibody positive by western blot and/or RIPA. The sensitivity of these seven assays ranged from 93·2% to 100%, with the 'Recombinant HTLV-I' (Cambridge Bioscience) and 'Serodia HTLV-I' (Fujirebio) assays having the highest sensitivity (100%). The specificity of these assays ranged from 98·4% to 100%, with the Abbott assay having the highest specificity (99·5%, 100%) according to two different methods of evaluation. Whether the antigens used in any assay were whole disrupted virus or recombinant gene products made no difference. The low positive predictive values of some of these assays (71·8-91·7%), even in a high prevalence population, and the need for RIPA to test indeterminate sera, indicate that for routine screening of blood donors there is still room for improvement both in screening and confirmatory assays for HTLV-I/II.

AB - To evaluate the sensitivity and specificity of HTLV-I/ II assays, serum from 1100 pregnant Haitian women was tested with seven commercially available HTLV I/II assays. Serum that was found to be reactive in any assay was analysed by western blot and all indeterminate samples were further characterised by radioimmunoprecipitation assays (RIPA). 59 (5·4%) samples were HTLV I/II antibody positive by western blot and/or RIPA. The sensitivity of these seven assays ranged from 93·2% to 100%, with the 'Recombinant HTLV-I' (Cambridge Bioscience) and 'Serodia HTLV-I' (Fujirebio) assays having the highest sensitivity (100%). The specificity of these assays ranged from 98·4% to 100%, with the Abbott assay having the highest specificity (99·5%, 100%) according to two different methods of evaluation. Whether the antigens used in any assay were whole disrupted virus or recombinant gene products made no difference. The low positive predictive values of some of these assays (71·8-91·7%), even in a high prevalence population, and the need for RIPA to test indeterminate sera, indicate that for routine screening of blood donors there is still room for improvement both in screening and confirmatory assays for HTLV-I/II.

UR - http://www.scopus.com/inward/record.url?scp=0025970551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025970551&partnerID=8YFLogxK

U2 - 10.1016/0140-6736(91)93343-8

DO - 10.1016/0140-6736(91)93343-8

M3 - Article

C2 - 1670658

AN - SCOPUS:0025970551

VL - 337

SP - 30

EP - 33

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8732

ER -